Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 3 2

Status

Recruiting 3Active not recruiting 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 3Gynecologic 2Thoracic 1Breast 1

Conditions

Prostatic Neoplasms 3Ovarian Neoplasms 2Endometrial Neoplasms 2Neoplasms 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 130Carboplatin 106Paclitaxel 65Cisplatin 61Gemcitabine 59Pemetrexed 57Bevacizumab 54Docetaxel 49Fluorouracil 43Oxaliplatin 41atezolizumab 37Dexamethasone 36Leucovorin 34Cetuximab 33130-nm albumin-bound paclitaxel 33Nivolumab 30Cyclophosphamide 30Prednisone 29Rituximab 28Capecitabine 28durvalumab 27Fulvestrant 24Lenalidomide 22enzalutamide 21Letrozole 21Irinotecan 21venetoclax 20Doxorubicin 19ribociclib 18pomalidomide 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × AZD5305 × 30 days × Clear all
NCT05797168 2026-06-03

FONTANA

AstraZeneca

Phase 1/2 Recruiting
506 enrolled
GynecologicThoracic

Adenocarcinoma of Lung, Ovarian Neoplasms, Endometrial Neoplasms

NCT05367440 2026-06-01

PETRANHA

AstraZeneca

Phase 1/2 Active not recruiting
174 enrolled
Genitourinary

Prostatic Neoplasms

NCT06120491 2026-05-27

EvoPAR-PR01

AstraZeneca

Phase 3 Active not recruiting
1,889 enrolled
Genitourinary

Prostatic Neoplasms

NCT06952803 2026-05-19

EvoPAR-PR02

AstraZeneca

Phase 3 Recruiting
700 enrolled
Genitourinary

Prostatic Neoplasms

NCT05123482 2026-05-18

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

AstraZeneca

Phase 1/2 Recruiting
460 enrolled
BreastGynecologic

Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡